Director Robert L. Zerbe MD of Vericel Corporation filed a statement of changes in beneficial ownership on November 6, 2026, reporting the exercise of stock options and the sale of common stock across two trading days, November 4 and November 5, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercises: Zerbe exercised stock options covering a total of 5,500 shares of Vericel Corp common stock at an exercise price of $13.05 per share across November 4 and November 5, 2026.
  • Shares sold: 5,500 shares were disposed of in three separate sale transactions at prices of $45.40, $55.00, and $51.67 per share, according to the filing.
  • Remaining beneficial ownership: Following all reported transactions, Zerbe directly owned 32,995 shares of common stock, the filing disclosed.
  • Remaining options: 2,000 stock options with an exercise price of $13.05 and an expiration date of May 2, 2028, remained beneficially owned after the reported transactions.
  • 10b5-1 plan: The filing states that all sales "were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2026."
  • Original grant: According to the filing, the options exercised "were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."

Zerbe's Option Exercises and Sales at Vericel Corporation

Vericel Corporation, listed on NASDAQ:VCEL, is a commercial-stage biopharmaceutical company. Director Robert L. Zerbe MD, whose address is listed care of Vericel Corporation at 25 Blue Sky Drive, Burlington, Massachusetts, reported a series of option exercise and stock sale transactions spanning November 4 and November 5, 2026, in a filing signed on November 6, 2026, by Sean Flynn as attorney-in-fact.

On November 4, 2026, Zerbe exercised 2,500 stock options at $13.05 per share, acquiring 2,500 shares of common stock, and immediately sold those 2,500 shares at $45.40 per share, leaving him with a direct beneficial ownership of 32,995 shares after that day's activity. On November 5, 2026, he conducted two additional rounds of option exercises: first, 500 options were exercised and 500 shares were sold at $55.00; second, 2,500 options were exercised and 2,500 shares were sold at $51.67 per share. After each of the November 5 sale transactions, the filing reports his direct share count returned to 32,995.

All sales are described in the filing as automatic transactions under a Rule 10b5-1 trading plan that Zerbe adopted on May 19, 2026. The options exercised across both days carried an exercise price of $13.05, an expiration date of May 2, 2028, and had been originally granted on May 2, 2018. The filing notes the options represented "the right to purchase a total of 17,500 shares" under the original grant, with 2,000 options remaining in Zerbe's direct ownership after the reported transactions.

What Was Disclosed

The filing reports that Vericel director Robert L. Zerbe MD exercised stock options and sold a combined 5,500 shares of common stock on November 4 and 5, 2026, under a pre-adopted 10b5-1 plan, leaving him with direct ownership of 32,995 shares and 2,000 remaining options.